SNORD96A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORD96A

NCBI ID: G619571

SNORD96A

Other Name(s): small nucleolar RNA, C/D box 96A | U96A | Small nucleolar RNA, C/D box 96A

SNORD96A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functional groups of snRNAs is the C/D box region, which is rich in conserved Secondary structure features and is involved in various cellular processes, including DNA replication, transcription, and translation. The C/D box region is also known as the H-score region and has been implicated in the interactions between snRNAs and DNA.

SNORD96A is a specific snRNA molecule that was identified as a potential drug target or biomarker using various bioinformatics and biochemical approaches. In this article, we will provide an overview of SNORD96A, including its structure, function, and potential as a drug target or biomarker.

Structure and Function

SNORD96A is a 231-nt RNA molecule that contains a unique C/D box region with a high scoring of 28.88. The C/D box region is composed of a parallel-like structure that consists of a central A-rich region and two secondary structures, a double-stranded loop and a stem-loop. The A-rich region is the most conserved part of the molecule and is involved in the formation of the double-stranded structure. The double-stranded loop is composed of two parallel loops and is the site of the C/D box RNA-protein interactions.

SNORD96A has been shown to play a role in various cellular processes, including cell growth, apoptosis, and DNA replication. In cell growth, SNORD96A has been shown to be involved in the regulation of cell cycle progression and the G1/S transition. In apoptosis , SNORD96A has been shown to be involved in the regulation of cell death and the transition from life to death. In DNA replication, SNORD96A has been shown to be involved in the regulation of DNA replication and has been implicated in the repair of DNA damage.

As a potential drug target, SNORD96A has been shown to be a good candidate due to its unique structure and function. The C/D box region of SNORD96A is highly conserved and has been shown to interact with various proteins, including transcription factors and histone modifiers . Therefore, targeting SNORD96A with small molecules or antibodies may be an effective way to inhibit the activity of these proteins and potentially lead to the inhibition of cellular processes that are desired to be blocked.

In addition to its potential as a drug target, SNORD96A also has the potential as a biomarker. The C/D box region of SNORD96A is highly conserved and has been shown to be expressed in various tissues and cell types. Therefore, the expression of SNORD96A may be a reliable biomarker for certain diseases or conditions. For example, the expression of SNORD96A has been shown to be elevated in various cancer types, including breast cancer, and may be a potential biomarker for cancer diagnosis or progression.

Conclusion

SNORD96A is a unique small nucleolar RNA molecule that has been shown to play a role in various cellular processes. Its unique C/D box region and high scoring make it a potential drug target or biomarker. The high conservation of the C/D box region and its expression in various tissues make it a promising candidate for drug targeting. Further studies are needed to fully understand the role of SNORD96A in cellular processes and its potential as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 96A

The "SNORD96A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD96A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets